Related Experiment Video

Updated: May 28, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Targeted Complement Treatments in Glomerulopathies: A Comprehensive Review

Micaela Gentile1, Lucio Manenti2

  • 1UO Nefrologia, Dipartimento di Medicina e Chirurgia, Università di Parma, 43126 Parma, Italy.

Journal of Clinical Medicine
|February 13, 2025
PubMed

Insights

The complement system, crucial for immunity, can cause kidney injury (glomerulopathy) when overactivated. Research explores targeting complement pathways for novel glomerulopathy treatments.

Area of Science:

  • Immunology
  • Nephrology
  • Complement System Biology

Background:

  • The complement system is a key part of innate immunity, involving proteins that trigger inflammation.
  • While vital for host defense, uncontrolled complement activation can lead to tissue damage, including in the kidneys.
  • Glomerulopathies are kidney diseases with varied causes, and complement activation is increasingly recognized in their pathogenesis.

Purpose of the Study:

  • To review the complex relationship between complement pathways and glomerulopathies.
  • To highlight the role of complement activation in kidney disease development.
  • To explore potential therapeutic strategies targeting the complement system for glomerulopathies.

Main Methods:

  • Comprehensive literature review of studies on complement activation and glomerulopathies.
  • Analysis of the mechanisms linking complement pathways to kidney pathology.
  • Examination of existing and emerging therapeutic interventions, including eculizumab.

Main Results:

  • Inappropriate complement activation is a significant driver of glomerulopathy pathogenesis.
  • Targeting specific complement pathways offers a promising therapeutic avenue.
  • Eculizumab has demonstrated efficacy in treating complement-mediated diseases like atypical hemolytic uremic syndrome.

Conclusions:

  • Understanding the interplay between complement and glomerulopathies is critical for advancing kidney disease treatment.
  • Targeted complement inhibition represents a significant therapeutic development for specific glomerulopathies.
  • Further research into complement modulation holds promise for improving patient outcomes in kidney diseases.

Keywords:
complement systemglomerulopathythrombotic microangiopathy

More Related Videos

Depletion of Specific Cell Populations by Complement Depletion06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

22.1K
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.5K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
386
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
432
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Renal Corpuscle01:20

Renal Corpuscle

The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
1.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131